HK1113797A1 - Quinoline derivative for the treatment of retinal diseases - Google Patents

Quinoline derivative for the treatment of retinal diseases

Info

Publication number
HK1113797A1
HK1113797A1 HK08109160.7A HK08109160A HK1113797A1 HK 1113797 A1 HK1113797 A1 HK 1113797A1 HK 08109160 A HK08109160 A HK 08109160A HK 1113797 A1 HK1113797 A1 HK 1113797A1
Authority
HK
Hong Kong
Prior art keywords
treatment
retinal diseases
quinoline derivative
quinoline
derivative
Prior art date
Application number
HK08109160.7A
Other languages
English (en)
Inventor
Thomas A Jordan
John E Dowling
John Clifford Chabala
Original Assignee
Aldexa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldexa Therapeutics Inc filed Critical Aldexa Therapeutics Inc
Publication of HK1113797A1 publication Critical patent/HK1113797A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08109160.7A 2005-05-26 2008-08-18 Quinoline derivative for the treatment of retinal diseases HK1113797A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68546005P 2005-05-26 2005-05-26
US72357705P 2005-10-04 2005-10-04
PCT/US2006/020320 WO2006127945A1 (en) 2005-05-26 2006-05-26 Compositions and methods of treating retinal disease

Publications (1)

Publication Number Publication Date
HK1113797A1 true HK1113797A1 (en) 2008-10-17

Family

ID=36928994

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08109160.7A HK1113797A1 (en) 2005-05-26 2008-08-18 Quinoline derivative for the treatment of retinal diseases

Country Status (14)

Country Link
US (12) US7973025B2 (ja)
EP (3) EP1888548B1 (ja)
JP (1) JP5042215B2 (ja)
KR (1) KR101342547B1 (ja)
CN (1) CN101321742B (ja)
AU (1) AU2006249866B2 (ja)
BR (1) BRPI0610308A8 (ja)
CA (1) CA2609659C (ja)
ES (2) ES2441873T3 (ja)
HK (1) HK1113797A1 (ja)
PL (1) PL1888548T3 (ja)
PT (1) PT1888548E (ja)
RU (2) RU2419610C2 (ja)
WO (1) WO2006127945A1 (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9510930B2 (en) 2008-10-22 2016-12-06 Contego Medical, Llc Angioplasty device with embolic filter
US9707071B2 (en) 2004-11-24 2017-07-18 Contego Medical Llc Percutaneous transluminal angioplasty device with integral embolic filter
PL1888548T3 (pl) 2005-05-26 2013-01-31 Neuron Systems Inc Pochodna chinoliny do leczenia schorzeń siatkówki
ES2449150T3 (es) * 2007-09-12 2014-03-18 The Trustees Of Columbia University In The City Of New York Compuestos y métodos para tratar la degeneración muscular
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
CA2782015C (en) * 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
KR101016018B1 (ko) 2010-02-18 2011-02-23 주식회사 세코닉스 피코 프로젝터용 투사 렌즈 유닛
AU2013361314A1 (en) * 2012-12-20 2015-07-02 Aldeyra Therapeutics, Inc. Peri-carbinols
KR102435676B1 (ko) 2013-01-23 2022-08-24 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
EP2948436A4 (en) * 2013-01-25 2016-07-13 Aldeyra Therapeutics Inc NOVEL CASES IN THE TREATMENT OF MACULAR GENERATION
JP2016520610A (ja) 2013-05-30 2016-07-14 モル リサーチ アプリケーションズ リミテッド 網膜変性疾患の治療のための組成物及び方法
ES2971592T3 (es) 2014-12-03 2024-06-06 Mor Research Applic Ltd Composiciones para el tratamiento de enfermedades degenerativas de la retina
BR112018003250A2 (pt) * 2015-08-21 2018-09-25 Aldeyra Therapeutics Inc compostos deuterados e usos dos mesmos
CA2996186A1 (en) * 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Aldehyde conjugates and uses thereof
MX2018010292A (es) 2016-02-28 2018-09-27 Aldeyra Therapeutics Inc Tratamiento de condiciones oculares alergicas con ciclodextrinas.
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CA3032609A1 (en) * 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
US20180050989A1 (en) * 2016-08-22 2018-02-22 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
KR101846730B1 (ko) 2016-11-01 2018-04-06 현대자동차주식회사 영상표시장치 마운팅 구조
WO2018170476A1 (en) * 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3077362A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
EP3824611A1 (en) * 2018-07-19 2021-05-26 Maersk Container Industry A/S Secure remote access to a reefer control system
WO2020028820A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7505786B2 (ja) 2018-09-25 2024-06-25 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患を処置するための製剤
WO2020118045A1 (en) * 2018-12-05 2020-06-11 Aldeyra Therapeutics, Inc. Injectable formulations
US12091388B2 (en) 2018-12-12 2024-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of Reproxalap
KR102651579B1 (ko) * 2018-12-18 2024-03-26 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 망막 질환용 화합물
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113767090B (zh) * 2019-12-30 2024-05-28 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
US20230131929A1 (en) * 2020-03-24 2023-04-27 Aldeyra Therapeutics, Inc. Quinoline compounds for treating respiratory disorders and viral infections
CA3174416A1 (en) * 2020-04-13 2021-10-21 Todd Brady Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. PHARMACEUTICAL FORMULATIONS AND USES THEREOF
CN115702144A (zh) * 2020-06-17 2023-02-14 南京明德新药研发有限公司 氨基吡啶类化合物
CN114981275B (zh) * 2020-12-29 2023-12-19 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) * 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU50906A1 (ru) 1935-12-20 1936-11-30 А.И. Бурляев Веретено дл пр дильных машин
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
JPS6192592A (ja) 1984-10-12 1986-05-10 Norin Suisansyo Shokuhin Sogo Kenkyusho 分岐サイクロデキストリンの製造方法
US4675332A (en) * 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) * 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
BR9106193A (pt) 1990-10-22 1993-03-23 Bausch & Lomb Metodo e composicao para limpar lentes de contato
CA2054339C (en) * 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
JP2746832B2 (ja) 1993-05-14 1998-05-06 大鵬薬品工業株式会社 眼局所抗アレルギー剤
GB9318431D0 (en) 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
US5767109A (en) 1993-10-20 1998-06-16 Sanchez; Robert A. Complexing urushiols
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
JP3297969B2 (ja) 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
FR2742053B1 (fr) 1995-12-06 1998-03-06 Chauvin Lab Sa Compositions pharmaceutiques a base de mequitazine
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
AU723758B2 (en) 1996-08-01 2000-09-07 Dow Agrosciences Llc 4-substituted quinoline derivatives having fungicidal activity
BR9710808A (pt) 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
ATE336485T1 (de) 1997-05-02 2006-09-15 Schering Ag Substituierte heterocyclen und deren verwendung in arzneimitteln
GB2327672A (en) * 1997-07-23 1999-02-03 Merck & Co Inc 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
IL134748A0 (en) 1997-09-02 2001-04-30 Du Pont Pharm Co Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6498154B1 (en) * 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP3568108B2 (ja) 1999-07-28 2004-09-22 松下電器産業株式会社 デジタル地図の位置情報伝達方法とそれを実施する装置
CA2392085A1 (en) 1999-11-15 2001-05-25 Smithkline Beecham Corporation Carvedilol methanesulfonate
AU1735001A (en) 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP4748289B2 (ja) 2000-06-23 2011-08-17 ライオン株式会社 点眼剤、眼科用組成物及び吸着抑制方法
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040198828A1 (en) 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
JP4564920B2 (ja) 2003-04-18 2010-10-20 株式会社最先端医学研究所 眼に適用する疾患治療剤
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
JP2005132834A (ja) 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
ES2426288T3 (es) * 2003-10-15 2013-10-22 Ube Industries, Ltd. Novedoso derivado de imidazol
BRPI0415863A (pt) 2003-10-27 2007-01-09 Astellas Pharma Inc derivados pirazina e seus usos farmacêuticos
AU2004293105B2 (en) 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
JP2005187407A (ja) 2003-12-25 2005-07-14 Lion Corp アレルギー眼疾患用眼科組成物
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
RU2006133300A (ru) 2004-02-17 2008-03-27 Президент Энд Феллоуз Оф Гарвард Колледж (Us) Управление течением офтальмологических расстройств, включая дегенерацию желтого пятна
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
CA2585210A1 (en) 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
EP1844768A1 (en) * 2005-01-19 2007-10-17 Dainippon Sumitomo Pharma Co., Ltd. Aromatic sulfone compound as aldosterone receptor modulator
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2006122183A2 (en) 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
PL1888548T3 (pl) 2005-05-26 2013-01-31 Neuron Systems Inc Pochodna chinoliny do leczenia schorzeń siatkówki
JP5196130B2 (ja) 2005-12-27 2013-05-15 ライオン株式会社 ソフトコンタクトレンズ用組成物及び吸着抑制方法
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
JP4466875B2 (ja) 2006-04-05 2010-05-26 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
KR20100110396A (ko) 2006-04-14 2010-10-12 프라나 바이오테크놀로지 리미티드 연령 관련 황반 변성（에이엠디）의 치료 방법
JP5194218B2 (ja) 2006-06-05 2013-05-08 株式会社メニコンネクト 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
CN101611009A (zh) 2006-07-25 2009-12-23 伊维沃制药股份有限公司 喹啉衍生物
JP2010500406A (ja) 2006-08-14 2010-01-07 シェーリング コーポレイション ５−（１（ｓ）−アミノ−２−ヒドロキシエチル）−ｎ−［（２，４−ジフルオロフェニル）−メチル］−２−［８−メトキシ−２−（トリフルオロメチル）−５−キノリン］−４−オキサゾールカルボキサミドの塩
RU2434630C2 (ru) 2006-08-31 2011-11-27 Юранд, Инк. Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US20080241256A1 (en) 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
WO2008157740A2 (en) 2007-06-20 2008-12-24 Ironwood Pharmaceuticals, Inc. Faah inhibitors
ES2615389T3 (es) 2007-10-05 2017-06-06 Acucela, Inc. Alcoxifenilpropilaminas para el tratamiento de la degeneración macular relacionada con la edad
AU2009213138B2 (en) 2008-02-11 2014-11-06 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
EP2331534A4 (en) 2008-08-12 2013-01-16 Sirtris Pharmaceuticals Inc BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGUES AS MODULATORS OF SIRTUINE
WO2010048332A2 (en) 2008-10-22 2010-04-29 Acucela, Inc. Compounds for treating ophthalmic diseases and disorders
US8680146B2 (en) 2008-11-11 2014-03-25 Novartis Ag Organic compounds
WO2010107525A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
WO2010133672A1 (en) 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
MX2011013061A (es) 2009-06-05 2012-02-28 Aciex Therapeutics Inc Formulaciones oftalmicas de fluticasona y metodos de uso.
WO2010148351A1 (en) 2009-06-18 2010-12-23 Cylene Pharmaceuticals, Inc. Rhodanines and related heterocycles as kinase inhibitors
WO2011008202A1 (en) 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
JPWO2011078204A1 (ja) 2009-12-24 2013-05-09 浜理薬品工業株式会社 高脂血症の予防または治療剤、および抗疲労剤
MA34083B1 (fr) 2010-02-26 2013-03-05 Xenon Pharmaceuticals Inc Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
US8575221B2 (en) 2010-03-17 2013-11-05 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
WO2012030938A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
BR112013017943A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores receptores do tipo toll
US10463687B2 (en) 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
US9302013B2 (en) 2011-01-31 2016-04-05 Termira Ab Active principle for mitigating undesired medical conditions
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
US20130190500A1 (en) 2011-12-12 2013-07-25 Neuron Systems, Inc. Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
GB201200192D0 (en) 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
IN2015DN00538A (ja) 2012-08-01 2015-06-26 Lewis And Clark Pharmaceuticals Inc
MX2015005839A (es) 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
AU2013361314A1 (en) 2012-12-20 2015-07-02 Aldeyra Therapeutics, Inc. Peri-carbinols
KR102435676B1 (ko) 2013-01-23 2022-08-24 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
KR102055937B1 (ko) 2013-01-23 2019-12-13 셈누르 파마슈티칼스, 인코포레이티드 불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형
EP2948436A4 (en) 2013-01-25 2016-07-13 Aldeyra Therapeutics Inc NOVEL CASES IN THE TREATMENT OF MACULAR GENERATION
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
US9713330B1 (en) 2013-03-15 2017-07-25 Deuteria Agrochemicals, Llc Deuterium-enriched aldehydes
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
US10272106B2 (en) 2014-06-04 2019-04-30 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
JP6634034B2 (ja) 2014-06-25 2020-01-22 シネルジア・バイオ・サイエンシーズ・プライベイト・リミテッドＳｙｎｅｒｇｉａ Ｂｉｏ Ｓｃｉｅｎｃｅｓ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 医薬水中油型ナノエマルジョン
NO2721710T3 (ja) 2014-08-21 2018-03-31
MX2017002750A (es) 2014-09-02 2017-08-02 Singh Bhupinder Metodo para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
TW201628622A (zh) 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
US10363231B2 (en) 2014-11-24 2019-07-30 Case Western Reserve University Compounds and methods of treating ocular disorders
TWI832668B (zh) 2015-04-15 2024-02-11 英屬開曼群島商百濟神州有限公司 Ｂ-ｒａｆ激酶抑制劑的無定形形式、鹽酸鹽、甲磺酸鹽、２-羥基乙磺酸鹽、ｌ-酒石酸鹽或草酸鹽及其用途
BR112018003250A2 (pt) 2015-08-21 2018-09-25 Aldeyra Therapeutics Inc compostos deuterados e usos dos mesmos
CA2996186A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Aldehyde conjugates and uses thereof
MX2018010292A (es) 2016-02-28 2018-09-27 Aldeyra Therapeutics Inc Tratamiento de condiciones oculares alergicas con ciclodextrinas.
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US11865113B2 (en) 2016-06-06 2024-01-09 Lipidio Pharmaceuticals Inc. Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH)
US20180050989A1 (en) 2016-08-22 2018-02-22 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
CA3032609A1 (en) 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
MX2019003623A (es) 2016-09-28 2019-09-23 Medicon Pharmaceuticals Inc Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MY202008A (en) 2016-10-05 2024-03-28 Mitobridge Inc Crystalline and salt forms of ppar agonist compounds
WO2018170476A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3077362A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
WO2020018498A1 (en) 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
WO2020028820A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7505786B2 (ja) 2018-09-25 2024-06-25 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患を処置するための製剤
JP2022503994A (ja) 2018-10-02 2022-01-12 アルデイラ セラピューティクス， インコーポレイテッド コンタクトレンズ溶液およびキット
WO2020118045A1 (en) 2018-12-05 2020-06-11 Aldeyra Therapeutics, Inc. Injectable formulations
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US20230131929A1 (en) 2020-03-24 2023-04-27 Aldeyra Therapeutics, Inc. Quinoline compounds for treating respiratory disorders and viral infections
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. PHARMACEUTICAL FORMULATIONS AND USES THEREOF
WO2021248031A1 (en) 2020-06-04 2021-12-09 Aldeyra Therapeutics, Inc. Dry eye disease biomarkers and their use for treatment

Also Published As

Publication number Publication date
AU2006249866A1 (en) 2006-11-30
US11724987B2 (en) 2023-08-15
EP2325171B1 (en) 2013-10-09
CN101321742B (zh) 2012-08-29
EP2336117A1 (en) 2011-06-22
US20150209333A1 (en) 2015-07-30
EP1888548A1 (en) 2008-02-20
KR101342547B1 (ko) 2013-12-17
US20190210971A1 (en) 2019-07-11
US9364471B2 (en) 2016-06-14
US9265759B2 (en) 2016-02-23
US20170320829A1 (en) 2017-11-09
JP5042215B2 (ja) 2012-10-03
US7973025B2 (en) 2011-07-05
WO2006127945A1 (en) 2006-11-30
US20240174614A1 (en) 2024-05-30
US20180194733A1 (en) 2018-07-12
JP2008542291A (ja) 2008-11-27
US20230041335A1 (en) 2023-02-09
BRPI0610308A2 (pt) 2010-11-09
US9650342B2 (en) 2017-05-16
BRPI0610308A8 (pt) 2017-04-25
CA2609659C (en) 2014-01-28
EP1888548B1 (en) 2012-08-22
AU2006249866B2 (en) 2011-10-13
US20090182009A1 (en) 2009-07-16
PL1888548T3 (pl) 2013-01-31
US20070135481A1 (en) 2007-06-14
US20210269402A1 (en) 2021-09-02
PT1888548E (pt) 2012-10-30
KR20080081806A (ko) 2008-09-10
US10913722B2 (en) 2021-02-09
CN101321742A (zh) 2008-12-10
RU2419610C2 (ru) 2011-05-27
US10202348B2 (en) 2019-02-12
US8940764B2 (en) 2015-01-27
US9896419B2 (en) 2018-02-20
ES2393768T3 (es) 2012-12-27
RU2011103741A (ru) 2012-08-10
US20110263645A1 (en) 2011-10-27
RU2007148994A (ru) 2009-07-10
EP2325171A1 (en) 2011-05-25
US20150209345A1 (en) 2015-07-30
US8940721B2 (en) 2015-01-27
ES2441873T3 (es) 2014-02-06
CA2609659A1 (en) 2006-11-30
US20160168098A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
HK1113797A1 (en) Quinoline derivative for the treatment of retinal diseases
HK1215960A1 (zh) 用於治療視網膜變性疾病的改良方式
HK1207821A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
HK1138850A1 (en) Quinoline derivatives for the treatment of inflammatory diseases
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
ZA200710605B (en) New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
IL190779A0 (en) Compositions for treatment of eye diseases
PL2056863T3 (pl) Leczenie chorób oczu
EP1962869A4 (en) TREATMENT OF RESPIRATORY DISEASES
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1865952A4 (en) COMPOSITIONS CONTAINING HISTAMINES FOR THE TREATMENT OF ALLERGIES
GB0523964D0 (en) The treatment of ophthalmic diseases
IL190182A0 (en) 2-aminoalcohols for the treatment of neurodegenerative diseases
ZA200606780B (en) Compounds for the treatment of diseases
GB0523962D0 (en) The treatment of ophthalmic diseases
GB0523965D0 (en) The treatment of ophthalmic diseases
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
GB0700755D0 (en) The Treatment of ophthalmic diseases
GB0408297D0 (en) Indole derivatives for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: CHABALA, JOHN, CLIFFORD